Do you want to read an article? Please log in or register.
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX® for active, mild-to-moderate ulcerative colitis
United European Gastroenterol J.
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L
doi: 10.1177/2050640619864848.
RECOMMENDED
Inflammatory Bowel Disease
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1093/ecco-jcc/jjaa075.
Inflammatory Bowel Disease
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Inflamm Bowel Dis.
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D
doi: 10.1093/ibd/izz204.
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease
Therap Adv Gastroenterol.
Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H
doi: 10.1177/1756284819827689.
Inflammatory Bowel Disease
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Lancet Gastroenterol Hepatol.
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S
doi: 10.1016/S2468-
Inflammatory Bowel DiseaseFurther Publications
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis
J Med Internet Res.
Del Hoyo J, Nos P, Bastida G, Faubel R, Muñoz D, Garrido-Marín A, Valero-Pérez E, Bejar-Serrano S, Aguas M
doi: 10.2196/15505.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn's disease using real world data
J Crohns Colitis.
Pillai N, Lupatsch JE, Dusheiko M, Schwenkglenks M, Maillard M, Sutherland CS, Pittet VEH, Swiss IBD Cohort study group.
doi: 10.1093/ecco-jcc/jjz169.